A Phase 1 interventional study of Bexagliflozin and Probenecid in Type 2 Diabetes Mellitus, sponsored by Theracos. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-01.
Sponsored by Theracos · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Diabetes Mellitus, Type 2 by Theracos — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus, Type 2 · Theracos.
Among the 17 studies in Diabetes Mellitus, Type 2 by Theracos, this one is the 11th largest by enrollment, is one of 5 that started in 2017, is one of 9 in phase 1, and was the 15th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 17 studies in Diabetes Mellitus, Type 2 by Theracos is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 78 across the 17 interventional studies. Of the 16 that completed or were terminated, 16 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
Theracos is the lead sponsor of 21 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 9 (100%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Diabetes Mellitus, Type 2 by Theracos, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to examine the drug-drug interaction when given the study drug, bexagliflozin, with three commonly prescribed medications, probenecid, verapamil or rifampin. The study is to evaluate how safe the study drug is and how well the study drug is tolerated when taken with probenecid, verapamil or rifampin.
In this study, a total of 48 healthy subjects were enrolled and assigned to one of three groups of 16 subjects. Each group participated in an open-label, non-randomized, fixed-sequence studies to assess potential interaction of bexagliflozin tablets, 20 mg with probenecid, rifampin or verapamil.
Sequence 1: Bexagliflozin/probenecid Sixteen healthy subjects were dosed with bexagliflozin, qd and/or probenecid tablets, 500 mg, bid, in sequential order as follows: on Day 1 subjects took bexagliflozin; on Days 3 and 4 subjects took probenecid, bid; on Day 5 subjects took one bexagliflozin, and probenecid, bid; and on Day 6 subjects took probenecid tablets, 500 mg, bid.
Sequence 2: Bexagliflozin/rifampin Sixteen healthy subjects were dosed with bexagliflozin, qd and/or 600 mg of rifampin daily in sequential order as follows: on Day 1 subjects took one bexagliflozin tablet; on Days 3 to 5, subjects took rifampin once daily; on Day 6 subjects took one bexagliflozin tablet and rifampin; and on Day 7 subjects took rifampin.
Sequence 3: Bexagliflozin/verapamil Sixteen healthy subjects were dosed with bexagliflozin, and/or verapamil tablets, 120 mg in sequential order as follows: on Day 1 subjects took one bexagliflozin tablet, on Day 4 subjects took one verapamil tablet, 1 hour before taking a bexagliflozin tablet.
Subjects meeting the following Criteria were included::
Subjects who met any of the following criteria were excluded from the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sixteen healthy subjects were dosed with bexagliflozin, qd and/or probenecid tablets, 500 mg, bid, in sequential order as follows: on Day 1 subjects took bexagliflozin; on Days 3 and 4 subjects took probenecid, bid; on Day 5 subjects took one bexagliflozin, and probenecid, bid; and on Day 6 subjects took probenecid tablets, 500 mg, bid.
Drug: Bexagliflozin · Drug: Probenecid
Sixteen healthy subjects were dosed with bexagliflozin, qd and/or 600 mg of rifampin daily in sequential order as follows: on Day 1 subjects took one bexagliflozin tablet; on Days 3 to 5, subjects took rifampin once daily; on Day 6 subjects took one bexagliflozin tablet and rifampin; and on Day 7 subjects took rifampin.
Drug: Bexagliflozin · Drug: Rifampin
Sixteen healthy subjects were dosed with bexagliflozin, and/or verapamil tablets, 120 mg in sequential order as follows: on Day 1 subjects took one bexagliflozin tablet, on Day 4 subjects took one verapamil tablet, 1 hour before taking a bexagliflozin tablet.
Drug: Bexagliflozin · Drug: Verapamil
Bexagliflozin 20 mg, tablet; qd
Also known as: EGT0001442, EGT0001474
Probenecid tablets, 500 mg; bid
Also known as: Probalan
Rifampin, 600 mg (2 x 300 mg capsules); qd
Also known as: Rifadin
Verapamil hydrochloride tablet, 120 mg; qd
Also known as: Verelan
Cmax (Maximum Observed Plasma Concentration)
Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).
Time frame: Up to 48 hours
Tmax (Time of Maximum Observed Plasma Concentration)
Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).
Time frame: Up to 48 hours
T1/2 (Apparent Terminal Elimination Half-life)
Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).
Time frame: Up to 48 hours
AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)
Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).
Time frame: Up to 48 hours
Urinary Glucose Excretion 0-48 hr
Pre-dose urine samples were collected from -12 to 0 h for baseline measurement of pharmacodynamic parameters. Post-dose urine samples were collected without preservative in four batches: 0 to 12 h, 12 to 24 h, 24 to 36h, and 36 to 48 h after dosing. Urine aliquots were prepared from well mixed collections for the assessment of pharmacodynamics.
Time frame: 0 to 48 hours
| Milestone | Bexagliflozin, Then Probenecid, Then Bexagliflozin and Probenecid | Bexagliflozin, Then Rifampin, Then Bexagliflozin and Refampin | Bexagliflozin, Then Verapamil and Bexagliflozin |
|---|---|---|---|
| Started | 16 | 16 | 16 |
| Completed | 16 | 16 | 16 |
| Not completed | 0 | 0 | 0 |
Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).
| ng/mL | Study 1: Bexagliflozin Alone | Study 1: Bexagliflozin and Probenecid | Study 2: Bexagliflozin Alone | Study 2: Bexagliflozin and Rifampin | Study 3: Bexagliflozin Alone | Study 3: Bexagliflozin and Verapamil |
|---|---|---|---|---|---|---|
| Cmax (Maximum Observed Plasma Concentration) | 161.675 ± 28.673 | 193.366 ± 22.098 | 97.811 ± 53.903 | 117.001 ± 60.097 | 159.355 ± 35.396 | 169.000 ± 24.727 |
Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).
| hours | Bexagliflozin/Probenecid | Bexagliflozin/Rifampin | Bexagliflozin/Verapamil |
|---|---|---|---|
| Bexagliflozin alone | 2.000 (2.000 to 4.000) | 2.000 (2.000 to 4.083) | 3.0 (2.000 to 8.000) |
| Bexagliflozin + additional drug | 3.000 (2.000 to 4.017) | 2.000 (1.017 to 4.000) | 3.000 (2.000 to 4.000) |
Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).
| hours | Bexagliflozin/Probenecid | Bexagliflozin/Rifampin | Bexagliflozin/Verapamil |
|---|---|---|---|
| Bexagliflozin alone | 12.090 ± 35.950 | 12.190 ± 36.966 | 10.709 ± 44.103 |
| Bexagliflozin + additional drug | 13.894 ± 24.806 | 5.318 ± 49.740 | 11.675 ± 48.222 |
Whole venous blood samples of 3 mL were collected from a peripheral vein prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h after administration of bexagliflozin; On Day 1 and Day 5 for Study 1, Day 1 and Day 6 for Study 2, Day 1 and Day 4 for Study 3. The pharmacokinetic parameters were estimated from the bexagliflozin plasma concentration data for each subject by non-compartmental analysis (NCA).
| hr*ng/mL | Study 1: Bexagliflozin Alone | Study 1: Bexagliflozin/Probenecid | Study 2: Bexagliflozin Alone | Study 2: Bexagliflozin/Rifampin | Study 3: Bexagliflozin Alone | Study 3: Bexagliflozin/Verapamil |
|---|---|---|---|---|---|---|
| AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity) | 1118.741 ± 23.290 | 1583.188 ± 23.676 | 698.254 ± 43.945 | 601.334 ± 49.870 | 1025.101 ± 25.746 | 1003.931 ± 21.571 |
Pre-dose urine samples were collected from -12 to 0 h for baseline measurement of pharmacodynamic parameters. Post-dose urine samples were collected without preservative in four batches: 0 to 12 h, 12 to 24 h, 24 to 36h, and 36 to 48 h after dosing. Urine aliquots were prepared from well mixed collections for the assessment of pharmacodynamics.
| g | Study 1: Bexagliflozin Alone | Bexagliflozin/Probenecid | Study 2: Bexagliflozin Alone | Bexagliflozin/Rifampin | Study 3: Bexagliflozin Alone | Bexagliflozin/Verapamil |
|---|---|---|---|---|---|---|
| Pre-dose (-12 - 0 hours) | 0.02 ± 0.024 | 0.47 ± 1.160 | 0.02 ± 0.014 | 0.12 ± 0.180 | 0.02 ± 0.018 | 1.37 ± 1.476 |
| 0 - 12 hours post-dose | 25.04 ± 5.579 | 25.90 ± 5.214 | 31.50 ± 9.272 | 31.40 ± 7.363 | 31.14 ± 5.814 | 31.46 ± 14.835 |
| 12 - 24 hours post-dose | 21.28 ± 7.347 | 20.92 ± 4.358 | 19.43 ± 6.863 | 15.72 ± 7.259 | 22.30 ± 3.933 | 20.51 ± 5.940 |
| 24 - 36 hours post-dose | 22.04 ± 7.136 | 22.10 ± 6.826 | 21.51 ± 7.668 | 16.32 ± 6.370 | 24.54 ± 6.517 | 20.94 ± 6.745 |
| 36 - 48 hours post-dose | 11.15 ± 5.447 | 9.53 ± 3.114 | 6.99 ± 3.440 | 3.41 ± 2.318 | 11.31 ± 4.997 | 4.78 ± 2.941 |
| 0 - 24 hours post-dose | 47.73 ± 9.125 | 46.82 ± 8.530 | 50.93 ± 15.606 | 47.12 ± 13.790 | 53.44 ± 8.712 | 51.97 ± 13.658 |
| 0 - 48 hours post-dose | 81.67 ± 16.083 | 78.44 ± 15.653 | 79.43 ± 24.490 | 66.86 ± 19.564 | 89.29 ± 16.461 | 77.69 ± 16.497 |
Collected over The adverse event data were collected from Day 0 up to Day 7 for study 1, Day 0 up to Day 8 for study 2 and Day 0 up to Day 6 for study 3 after drug administration. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Study 1: Bexagliflozin Alone | 0/16 (0%) | 0/16 (0%) | 0/16 (0%) |
| Study 1: Bexagliflozin and Probenecid | 0/16 (0%) | 0/16 (0%) | 1/16 (6.3%) |
| Study 2: Bexagliflozin Alone | 0/16 (0%) | 0/16 (0%) | 0/16 (0%) |
| Study 2: Bexagliflozin and Rrifampin | 0/16 (0%) | 0/16 (0%) | 0/16 (0%) |
| Study 3: Bexagliflozin Alone | 0/16 (0%) | 0/16 (0%) | 2/16 (12.5%) |
| Study 3: Bexagliflozin and Verapamil | 0/16 (0%) | 0/16 (0%) | 0/16 (0%) |
| Event | Study 1: Bexagliflozin Alone | Study 1: Bexagliflozin and Probenecid | Study 2: Bexagliflozin Alone | Study 2: Bexagliflozin and Rrifampin | Study 3: Bexagliflozin Alone | Study 3: Bexagliflozin and Verapamil |
|---|---|---|---|---|---|---|
| DiarrheaGastrointestinal disorders | 0/16 | 1/16 | 0/16 | 0/16 | 0/16 | 0/16 |
| Gastrointestinal sounds abnormalGastrointestinal disorders | 0/16 | 1/16 | 0/16 | 0/16 | 0/16 | 0/16 |
| LacerationInjury, poisoning and procedural complications | 0/16 | 0/16 | 0/16 | 0/16 | 1/16 | 0/16 |
| PresyncopeNervous system disorders | 0/16 | 0/16 | 0/16 | 0/16 | 1/16 | 0/16 |
| Age, Continuous(years) | Bexagliflozin, Then Probenecid, Then Bexagliflozin and Probenecid | Bexagliflozin, Then Rifampin, Then Bexagliflozin and Refampin | Bexagliflozin, Then Verapamil and Bexagliflozin | Total |
|---|---|---|---|---|
| Mean | 38.4 ± 9.69 | 35.3 ± 10.72 | 37.8 ± 11.24 | 37.2 ± 10.43 |
| Sex: Female, Male(Participants) | Bexagliflozin, Then Probenecid, Then Bexagliflozin and Probenecid | Bexagliflozin, Then Rifampin, Then Bexagliflozin and Refampin | Bexagliflozin, Then Verapamil and Bexagliflozin | Total |
|---|---|---|---|---|
| Female | 3 | 5 | 4 | 12 |
| Male | 13 | 11 | 12 | 36 |
| Ethnicity (NIH/OMB)(Participants) | Bexagliflozin, Then Probenecid, Then Bexagliflozin and Probenecid | Bexagliflozin, Then Rifampin, Then Bexagliflozin and Refampin | Bexagliflozin, Then Verapamil and Bexagliflozin | Total |
|---|---|---|---|---|
| Hispanic or Latino | 10 | 8 | 8 | 26 |
| Not Hispanic or Latino | 6 | 8 | 8 | 22 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Bexagliflozin, Then Probenecid, Then Bexagliflozin and Probenecid | Bexagliflozin, Then Rifampin, Then Bexagliflozin and Refampin | Bexagliflozin, Then Verapamil and Bexagliflozin | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 2 | 5 | 12 |
| White | 11 | 14 | 11 | 36 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Weight(kg) | Bexagliflozin, Then Probenecid, Then Bexagliflozin and Probenecid | Bexagliflozin, Then Rifampin, Then Bexagliflozin and Refampin | Bexagliflozin, Then Verapamil and Bexagliflozin | Total |
|---|---|---|---|---|
| Mean | 81.3 ± 10.59 | 74.1 ± 11.31 | 78.9 ± 9.21 | 78.7 ± 10.57 |
| Height(cm) | Bexagliflozin, Then Probenecid, Then Bexagliflozin and Probenecid | Bexagliflozin, Then Rifampin, Then Bexagliflozin and Refampin | Bexagliflozin, Then Verapamil and Bexagliflozin | Total |
|---|---|---|---|---|
| Mean | 170.9 ± 8.28 | 169.2 ± 8.38 | 172.1 ± 10.17 | 170.7 ± 8.88 |
| BMI(kg/m^2) | Bexagliflozin, Then Probenecid, Then Bexagliflozin and Probenecid | Bexagliflozin, Then Rifampin, Then Bexagliflozin and Refampin | Bexagliflozin, Then Verapamil and Bexagliflozin | Total |
|---|---|---|---|---|
| Mean | 27.8 ± 2.73 | 25.9 ± 3.31 | 26.7 ± 2.46 | 27.0 ± 3.50 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2017 to primary completion in Dec 2017, 2 months.
Results were first posted in Apr 2021, 3 years 4 months after primary completion.
Of 454 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 2 months is below that.
Counting every sponsor, half of 516 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Theracos